Fourteen pharmaceutical stocks in Top 100.. Green Cross Holdings Corp. Pfd. Series 2 leads the ranking, followed by Shin Poong Pharmaceutical Co.
Pharmaceutical stocks turned to a bear market in September, but they got high ranks in Q3 stock’s performance with a rise in July and August (based on adjusted stock price).
In Q3, 6 pharmaceutical stocks ranked in the top in the stock price increase among 906 stocks listed on the securities market, according to the Korea Exchange.
Including them, 8 pharmaceutical stocks were listed in the top 50 and 14 in the top 100, with 20 stocks in the top 200.
As for the stock price increase rate, 7 pharmaceutical stocks recorded a three-digit increase rate during this period, and 34 pharmaceutical stocks, including these, made a double-digit increase rate.
By stock, Green Cross Holdings Corp. Pfd. Series 2’s share price increased 460.95% in Q3, the highest growth rate among 906 stocks in the securities market.
Shin Poong Pharmaceutical Co. Ltd. also gained 318.87% over the same period but was ranked second behind Green Cross Holdings Corp. Pfd. Series 2.
Shin Poong Pharmaceutical Co. Ltd. Pfd. Series 1 was ranked fourth with a rate of 255.77%, GeneOneLifeScience ranked 6th with 250.99%, Korea United Pharm placed 7th with 202.08%, and ORIENTBIO came in at 10th with 168.15%, listing on the top 10.
Wooridul Pharmaceutical also recorded a three-digit increase rate of 133.23% but could not reach the top 10 with 13th.
Hanmi Science placed 39th with 76.58%, entering in the 50th, Yuyu Pharma Inc. Pfd. Series 2 61st with 56.17%, Yuyu Pharma Inc. Pfd. Series 1 67th with 54.20%, Chong Kun Dang Pharmaceutical 72nd with 53.00%, Green Cross 79th with 49.66%, Yungjin Pharm 84th with 47.46%, and JW Pharmaceutical Corp. Pfd. Series 2 91st with 45.58%, involving in the top 100.
Kukje Pharma rose 42.57% but failed to make the top 100, with 103rd.
Kwang Dong Pharmaceutical, Dong Wha Pharm, Reyon Pharmaceutical, and Dong-A Socio Holdings reached over a 30% increase rate and entered the top 200 with Yuhan with 26.88%.
Il-Yang Pharmaceutical, Samil Pharmaceutical, Myungmoon Pharmaceutical, and HanAll BioPharma recorded above 20% and went into 300th with Yuyu Pharma, Il-Yang Pharmaceutical Co. Ltd. Pfd. Series 1, Daewon Pharmaceutical, JW Pharmaceutical Corp. Pfd. Series 1, Yuhan Corp. Pfd. Series 1, Kyongbo Pharmaceutical. CKD Bio, Daewoong, Il Dong Pharmaceutical, and Hanmi Pharmaceutical came in 350th.
